President & CEO, Centre for Commercialization of Regenerative MedicineMichael May is President and Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies and launches new companies by supporting both academic and industry activities in the field of regenerative medicine, including cell and gene therapy. With a staff of 50, a network of academic members, 50+ industry partners, dedicated funding and facilities to develop technologies, manufacture cell product and incubate companies, CCRM is generating health and economic benefits for its stakeholders. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity.
Michael sits on a number of boards and advisory committees including: MaRS Innovation; the Ontario Institute of Regenerative Medicine (OIRM); the Centre for the Commercialization of Antibodies and Biologics (CCAB); The Centre for Phenogenomics (TCP); the Department of Chemical Engineering and Applied Chemistry at the University of Toronto; the Industry Committee of the International Society for Stem Cell Research (ISSCR); the Executive Committee, Alliance for Regenerative Medicine (ARM); ExCellThera Ltd.; the Rick Hansen Institute Commercialization Program Advisory Committee; Toronto Region Board of Trade Life Sciences Steering Committee; the NSERC CREATE M3 Program Committee; and the Cell and Gene Therapy Insights, Editorial Advisory Board.
Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.